Abstract Overview: Phase II Study of Talimogene Laherparepvec and Ipilimumab in Melanoma - 102164

Spotlight
Video

Abstract Overview: Phase II Study of Talimogene Laherparepvec and Ipilimumab in Melanoma

Loading........
Description: Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center gives an overview of his presentation which focused on the use of talimogene laherparepvec and ipilimumab versus ipilimumab alone in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma
Shared By : AnnualMeeting2017
Posted on : 06/05/17
Added : 12 months ago